SCHEMBL2758280

SCHEMBL2758280

CC(C)(C)CCN1CCC2(CC1)C[C@H](NC(=O)C1CC1)c1ccccc12

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCHR2 Q969V1 8/20 0.46
DRD2 P14416 5/20 0.44
KCNH2 Q12809 3/20 0.44
SLC6A4 P31645 2/20 0.44
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
CACNA1I Q9P0X4 2/20 0.38
HTR2A P28223 3/20 0.37
DRD3 P35462 3/20 0.37
OPRM1 P35372 1/20 0.37
OPRL1 P41146 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD11B1 P28845 1/20 0.36
HSD11B2 P80365 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2758224 0.96 MCHR2 (0.45) MCHR2DRD2KCNH2SLC6A4ALDH1A1
SCHEMBL2758156 0.94 MCHR2 (0.39) MCHR2DRD2KCNH2SLC6A4ALDH1A1
SCHEMBL2758003 0.94 MCHR2 (0.39) MCHR2DRD2KCNH2SLC6A4ALDH1A1
SCHEMBL2758229 0.90 MCHR2 (0.48) MCHR2DRD2KCNH2SLC6A4CACNA1I
SCHEMBL2758244 0.89 MCHR2 (0.57) MCHR2DRD2KCNH2SLC6A4CACNA1I
SCHEMBL2758208 0.87 DRD2 (0.43) MCHR2DRD2KCNH2SLC6A4HTR2A
SCHEMBL2758187 0.87 DRD2 (0.43) MCHR2DRD2KCNH2SLC6A4HTR2A
SCHEMBL2758272 0.87 MCHR2 (0.47) MCHR2DRD2KCNH2SLC6A4CACNA1I
SCHEMBL2758094 0.86 MCHR2 (0.38) MCHR2DRD2KCNH2SLC6A4ALDH1A1
SCHEMBL2758188 0.86 MCHR2 (0.38) MCHR2DRD2KCNH2SLC6A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304423-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-11-06 US disclosed
US-8304423-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-11-06 US disclosed
US-20120196857-A9 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-02 US disclosed
US-20120196857-A9 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-02 US disclosed
US-20120004226-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-05 US disclosed
US-20120004226-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-05 US disclosed
US-8003660-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-08-23 US disclosed
US-8003660-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-08-23 US disclosed
US-20070213315-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2007-09-13 US disclosed
US-20070213315-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213315-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 MCHR2 159/4885DRD2 757/4885KCNH2 571/4885
US-20120004226-A1 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 MCHR2 159/4885DRD2 757/4885KCNH2 571/4885
US-20120196857-A9 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 MCHR2 159/4885DRD2 757/4885KCNH2 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.